Sanofi India Limited (SANOFI)
Outcome of Board Meeting
Q2FY27 results (unaudited):
Standalone:
Revenue 4.4bn +8% y-y (4.1bn)
PAT 0.8bn +20% y-y (0.7bn)
Half year FY27 results (unaudited):
Standalone:
Revenue 9.1bn -3% y-y (9.4bn)
PAT 1.9bn -2% y-y (1.9bn)
FY25 results (audited):
Standalone:
Revenue 18.4bn
PAT 3.3bn
Dividend: Dividend paid of 1.1bn for half year ended June 30, 2026
Commentary: Q2 2026 marks another chapter of purposeful, profitable growth for Sanofi India, with double-digit growth in diabetes portfolio and profit before tax growing 19%.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 SANOFI — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add SANOFI to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Sanofi India Limited
Important.
The summary above is generated automatically from Sanofi India Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.